Stroke: Vascular and Interventional Neurology (Nov 2021)

Abstract 1122‐000029: Pharmacological and Clinical Factors Associated with Gender Difference in Alzheimer Dementia Patients

  • Samuel I Imeh‐Nathaniel,
  • Oreoluwa O Coker‐Ayo,
  • Liddy Agbomi,
  • Nneoma Madubike,
  • Chika Pamela,
  • Nicolas Poupore,
  • Melissa J Bailey‐Taylor,
  • Laurie Theriot Roley,
  • Richard L Goodwin,
  • Brooks McPhail,
  • Rebecca Russ‐Sellers,
  • Thomas I Nathaniel

DOI
https://doi.org/10.1161/SVIN.01.suppl_1.000029
Journal volume & issue
Vol. 1, no. S1

Abstract

Read online

Introduction: Alzheimer dementia (AD) has been reported in both men and women. However, factors contributing to gender differences are not fully understood. We tested the hypothesis that specific pharmacological, demographic, and risk factors contribute to gender difference in AD. Methods: A retrospective analytical approach was used to analyze data from 12,632 AD patients, comprising 4,584 men and 8,048 women. Univariate and multivariate analyses determined the factors contributing to the gender difference in AD patients. Results: About 36% of AD patients were men, and 64% were women. Citalopram (OR = 1.187, 95% CI, 1.044 – 1.350, P = 0.009) was associated with men, while escitalopram (OR = 1.213, 95% CI, 1.119 – 1.315, P<0.001) was associated with women. In both men and women, increasing age (OR = 1.075, 95% CI, 1.071 – 1.079, P<0.001/OR = 1.096, 95% CI, 1.093 – 1.100, P<0.001), tobacco use (OR = 1.150, 95% CI, 1.054 – 1.254, P = 0.002/OR = 1.150, 95% CI, 1.073 – 1.233, P<0.001), and black patients (OR = 2.380, 95% CI, 2.120 – 2.674, P<0.001/OR = 1.395, 95% CI, 1.268 – 1.535, P<0.001) were associated with AD. Conclusions: Our findings reveal similarities and differences in factors associated with both men and women AD patients, suggesting the development of management strategies for the care of AD.

Keywords